Jason B. Cross

An inhibitor of oxidative phosphorylation exploits cancer vulnerability

Jennifer R. Molina, Yuting Sun, Marina Protopopova et al. · Nature Medicine · 2018 · 951 citations · Full text

Medicine, Cancer Biology, Oncology +14

Comparison of Several Molecular Docking Programs: Pose Prediction and Virtual Screening Accuracy

Jason B. Cross, David C. Thompson, Junaid Baber et al. · Journal of Chemical Information and Modeling · 2009 · 455 citations

Pharmacy, Bioinformatics, Medicinal Chemistry +17

Structure-based classification predicts drug response in EGFR-mutant NSCLC

Jacqulyne Robichaux, Xiuning Le, R. S. K. Vijayan et al. · Nature · 2021 · 452 citations · Full text

Medicine, Molecular Genetics, Oncology +14

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity

Jacqulyne Robichaux, Yasir Y. Elamin, R. S. K. Vijayan et al. · Cancer Cell · 2019 · 241 citations · Full text

Medicine, Oncology, Pharmacology +14

Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib

Yuting Sun, Brooke A. Meyers, Barbara Czakó et al. · Cancer Research · 2020 · 106 citations · Full text

Medicine, Oncology, Pharmacology +17